Drug intelligence / Profile preview

Ceftrimed

Development stage: Unknown
Lead developer: Nutramedica
Modality: Small Molecules
Administration: Oral

Overview

Ceftrimed is an oral third-generation cephalosporin antibiotic containing cefixime as the active ingredient. Developed and marketed by Nutramedica Inc. in the Philippines, it is primarily used to treat pediatric bacterial infections such as otitis media and respiratory tract infections. The drug functions by binding to bacterial penicillin-binding proteins (PBPs), thereby inhibiting the synthesis of the bacterial cell wall and leading to cell lysis. It is available in pediatric-specific formulations, such as granules for oral suspension at a concentration of 100 mg/5 mL.

Brand names: Ceftrimed
Other names: cefixime

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on Ceftrimed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ceftrimed.

Explore the full profile